LIFERIVER(SH:688317)2025-01-17 09:50Financial Performance - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -163 million yuan and -110 million yuan[2]. - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is also projected to be between -163 million yuan and -110 million yuan[2]. - In the same period last year, the net profit attributable to shareholders of the parent company was -136.86 million yuan[3]. - The total profit for the previous year was -156.63 million yuan, with a net profit after deducting non-recurring gains and losses of -155.24 million yuan[3]. Revenue and Market Dynamics - The decline in revenue is attributed to a decrease in sales of self-developed molecular diagnostic reagents and equipment due to changes in market demand[4]. Strategic Initiatives - The company has increased investment in product research and development and is expanding its product lines[5]. - Marketing efforts are being strengthened in areas such as respiratory diseases, gynecological tumors, and liver diseases, while actively exploring international markets[5]. - The company is implementing cost reduction and efficiency enhancement measures to improve operational management efficiency and profitability[5]. Forecast and Uncertainties - There are no significant uncertainties affecting the accuracy of this earnings forecast[6]. - The forecast data is preliminary and subject to change upon the release of the audited annual report for 2024[7].